HI-Bio

Acquired

Precision therapies for immune-mediated disease.

South San Francisco, United States · Founded 2020 · $215.0M raised

Employees
11–50
Founded
2020
Business Model
B2B
Website
hi-bio.com
Total Funding
$215.0M
Last Round
$95.0M Series BJan 2024
Rounds
2
Acquired by
GileadMay 2024 · $1.8B

About

HI-Bio is a clinical-stage biotechnology company developing precision therapies for severe immune-mediated diseases. The company's pipeline targets conditions with high unmet need including IgA nephropathy, atopic dermatitis, and alopecia areata, using a mechanism-based approach to selectively disrupt disease-driving immune pathways. Founded in 2020 and headquartered in South San Francisco, HI-Bio raised $70M in Series B financing in October 2023 before being acquired by Gilead Sciences in 2024 for approximately $1.15 billion.

Summary

HI-Bio is a Biotech company based in South San Francisco, United States, founded in 2020. It has raised $215.0M in total across 2 rounds, most recently a $95.0M Series B round in Jan 2024.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionMay 2024

Sign up to see all 3 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

HI-Bio on Indexed.vc
<a href="https://indexed.vc/companies/hi-bio"><img src="https://indexed.vc/api/badge/company/hi-bio" alt="HI-Bio on Indexed.vc" width="260" height="76" /></a>